Intrathoracic Administration of Recombinant Human Tumor Necrosis Factor-alpha with Closed Small Tube Drainage for Malignant Pleural Effusions: a Phase Ⅲ Clinical Study
Huining CHEN,Guanping ZHANG,Wei GE
DOI: https://doi.org/10.3969/j.issn.1671-8852.2006.06.032
2006-01-01
Abstract:Objective: To assess the efficacy and safety of intrathoracic administration of recombinant human tumor necrosis factor-alpha (rhTNF-α) with closed small tube drainage for the treatment of malignant pleural effusions. Methods: From October 2001 to September 2004, 46 patients with moderate to volume of malignant pleural effusions (29 cases of lung cancer, 7 breast cancer, 2 cervix cancer, 1 ovarian cancer, 3 malignant lymphoma and 4 gastric carcinoma) had been studied. Closed small tube drainage was performed in all patients. After complete drainage, 25 mg indomethacin was administered, and half an hour later, 3 million units rhTNF-α was injected intraplurally through the small tube before the drainage was closed. Twenty hours later, the effusion was drained again. If there were still effusions, the intrathoracic administration of rhTNF-α was repented. Afterwards, the above treatment was repented three times per week for 3-4 weeks or until the drained effusions were less than 150 ml in 24 hours. Results: Circled digit one Efficacy: Of the 46 patients included, complete response (CR) was shown in 27 patients (58.70%), partial response (PR) in 17 (36.96%), stable disease in 3 (6.52%) and progressive disease in no patient. The overall response rate (CR+PR) was 93.48%. Circled digit two Side-effects: 19 patients (41.30%) had chest pain (grade I-II), fever (grade I) and rigor (grade I) were observed in 9 (19.56%) and 2 patients (4.35%) respectively. Other side-effects, such as pneumothorax, infection, pleural response, edema, low blood pressure, low pulse pressure, arrhythmia, liver and kidney dysfunction, etc., were not observed. Conclusion: Intrathoracic administration of rhTNF-α with closed small tube drainage is effective in the treatment of malignant pleural effusions and with little toxicity.